# Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

> **NCT05477927** · PHASE1 · UNKNOWN · sponsor: **Sichuan University** · enrollment: 58 (estimated)

## Conditions studied

- Malignant Peritoneal Effusion
- Malignant Ascites
- Serous Cavity Metastatises

## Interventions

- **BIOLOGICAL:** Dual-targeting VEGFR1 and PD-L1 CAR-T cells

## Key facts

- **NCT ID:** NCT05477927
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-28
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477927, "Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05477927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*